The paradox of ApoA5 modulation of triglycerides: Evidence from clinical and basic research

Clinical Biochemistry

Volumn 46, Issue 1-2, 2013, Pages 12-19

  Garelnabi, Mahdi ^a   Lor, Kenton ^a   Jin, Jun ^a   Chai, Fei ^a   Santanam, Nalini ^b  

^a UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ApoA5 polymorphism; Atherosclerosis; Coronary artery disease; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A5; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CHROMOSOME 11Q; DNA SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; METABOLIC DISORDER; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; APOLIPOPROTEINS A; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIET; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METABOLIC SYNDROME X; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 84871783070     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.09.007     Document Type: Review

References (82)

1. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., Cox D.R., Fruchart J.C., Krauss R.M., Rubin E.M. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173.
2. Van Der Vliet H.N., Sammels M.G., Leegwater A.C., Levels J.H., Reitsma P.H., Boers W., Chamuleau R.A. Apolipoprotein A-V: a novel apolipoproein associated with an early phase liver regeneration. J Biol Chem 2001, 276:44512-44520.
3. Rensen P.C.N., van Dijk K.W., Havekes L.M. Apolipoprotein AV low concentration, high impact. Arterioscler Thromb Vasc Biol 2005, 25:2445-2447.
4. Van Der Vliet H.N., Schapp F.G., Levels J.H., Ottenhoff R., Looije N., Wesseling J.G., Groen A.K., Chamuleu R.A. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 2002, 295:1156-1159.
5. O'Brien P.J., Alborn W.E., Sloan J.H., Ulmer M., Boodhoo A., Knierman M.D., Shcultze A.E., Konrad R.J. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005, 51:351-359.
6. Weinberg R.B., Cook V.R., Beckstead J.A., Martin D.D., Gallagher J.W., Shelness G.S., Ryan R.O. Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 2003, 278:34438-34444.
7. Baroukh N., Bauge E., Akiyama J., Chang J., Afzal V., Fruchart J.C., Rubin E.M., Fruchart-Najib J., Pennacchio L.A. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 2004, 24:1297-1302.
8. Merkel M., Loeffler B., Kluger M., Fabig N., Geppert G., Pennacchio L.A., Laatsch A., Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005, 280:21553-21560.
9. Schaap F.G., Rensen P.C., Voshol P.J., Vrins C., Van Der Vliet H.N., Chamuleau R.A., Haveskes L.M., Groen A.K., van Dijk K.W. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004, 279:27941-27947.
10. Nowak M., Helleboid-Chapman A., Jakel H., Martin G., Duran-Sandoval D., Staels B., Rubin E.M., Pennacchio L.A., Taskinen M.R., Fruchart-Najib J., Fruchart J.C. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol Feb 2005, 25(4):1537-1548.
11. Nilsson Stefan K., Lookene Aivar, Beckstead Jennifer A., Gliemann Jørgen, Ryan Robert O., Olivecrona Gunilla Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 2007, 46(12):3896-3904.
12. Shu X., Nelbach L., Ryan R.O., Forte T.M. Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation. Biochim Biophys Acta May 2010, 1801(5):605-608.
13. Khovidhunkit W., Duchateau P.N., Medzihradszky K.F., Moser A.H., Naya-Vigne J., Shigenaga J.K., Kane J.P., Grunfeld C., Feingold K.R. Apolipoproteins A-IV and A-V are acute-phase proteins in mouse HDL. Atherosclerosis Sep 2004, 176(1):37-44.
14. Becker Steffi, Schomburg Lutz, Renko Kostja, Tölle Markus, Van Der Giet Markus, Tietge Uwe J.F. Altered apolipoprotein A-V expression during the acute phase response is independent of plasma triglyceride levels in mice and humans. Biochem Biophys Res Commun 2006, 20:833-839.
15. Hodoglugil U., Tanyolac S., Williamson D.W., Huang Y., Mahley R.W. Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turks. J Lipid Res 2006, 47:144-153.
16. Lai C.Q., Tai E.S., Tan C.E., Cutter J., Chew S.K., Zhu Y.P., Adiconis X., Ordovas J.M. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 2003, 44:2365-2373.
17. Kao J.T., Wen H.C., Chien K.L., Hsu H.C., Lin S.W. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003, 19:2533-2539.
18. Pennachio L.A., Olivier M., Hubacek J.A., Krauss R.M., Rubin E.M., Cohen J.C. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002, 11:3031-3038.
19. Chen S.N., Cilingiroglu M., Todd J., Lombardi R., Willerson J.T., Gotto A.M., et al. Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet 2009, 10:111.
20. Chien K.L., Hsu H.C., Chen Y.C., Su T.C., Lee Y.T., Chen M.F. Association between sequence variant of c.553 G>T in the apolipoprotein AS gene and metabolic syndrome, insulin resistance, and carotid atherosclerosis. Transl Res 2009, 154:133-141.
21. Elosua R., Ordovas J.M., Cupples L.A., Lai C.Q., Demissie S., Fox C.S., Polak J.F., Wolf P.A., D'Agostino R.B., O'Donell C.J. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res 2006, 47:990-996.
22. Talmud P.J., Palmen J., Putt W., Lins L., Humphries S.E. Determination of the functionality of common APOA5 polymorphisms. J Biol Chem 2005, 28215-28220.
23. Lai C.Q., Demissie S., Cupples L.A., Zhu Y., Adiconis X., Parnell L.D., Corella D., Ordovas J.M. Influence of the APOAT locus on plasma triglyceride, lipoprotein subclasses, and CVD risks in the Framingham Heart Study. J Lipid Res 2004, 45:2096-2105.
24. Ribalta J.L., Fernandez-Ballart J., Vilella E., Castro M., Masana L., Joven J. Newly identified apolipoprotein AV predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem 2002, 48:1597-1600.
25. Aouizerat B.E., Kulkarni B.E., Heilbron M., Drown D., Raskin S., Pullinger C.R., Malloy M.J., Kane J.P. Genetic variants of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res 2003, 44(6):1167-1173.
26. Shirts B.H., Howard M.T., Hasstedt S.J., Nanjee M.N., Knight S., Carlquist J.F., Anderson J.L., Hopkins P.N., Hunt S.C. Vitamin D dependent effects of APOA5 polymorphisms on HDL cholesterol. Atherosclerosis May 2012, 222(1):167-174.
27. Calandra S., Priore Oliva C., Tarugi P., Bertolini S. APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol Apr 2006, 17(2):122-127.
28. Grosskopf I., Baroukh N., Lee S.J., Kamari Y., Harats D., Rubin E.M., Pennacchio L.A., Cooper A.D. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol Dec 2005, 25(12):2573-2579.
29. Charlton-Menys V., Durrington P.N. Apolipoprotein A5 and hypertriglyceridemia. Clin Chem Feb 2005, 51(2):295-297.
30. Nabika T., Nasreen S., Kobayashi S., Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis 2002, 165:201-204.
31. Endo K., Yanagi H., Araki J., Hirano C., Yamakawa-Kobayashi K., Tomura S. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 2002, lll:570-572.
32. Grallert H., Sedlmeier E.M., Huth C., Kolz M., Heid I.M., Meisinger C., et al. APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res 2007, 48:2614-2621.
33. Jiang C.Q., Liu B., Cheung B.M., Lam T.H., Lin J.M., Li Jin Y., et al. A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese. Eur J Hum Genet 2010, 18:1255-1260.
34. Huang X.S., Zhao S.P., Zhang Q., Bai L., Hu M. Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome. Atherosclerosis 2009, 204:e99-e102.
35. Hyun Y.J., Jang Y., Chae J.S., Kim J.Y., Paik J.K., Kim S.Y., et al. Association of apolipoprotein AS concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men. Atherosclerosis 2009, 205:568-573.
36. Hsu L.A., Ko Y.L., Chang Q., Hu C.F., Wu S., Teng M.S., et al. Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 2006, 185:143-149.
37. Lee K.W., Ayyobi A.F., Frohlich J.J., Hill J.S. APOA5 gene polymorphism modulates levels of triglyceride, HDL cholesterol and FERHDL but is not a risk factor for coronary artery disease. Atherosclerosis 2004, 176:165-172.
38. Martinelli N., Trabetti E., Bassi A., Girelli D., Friso S., Pizzolo F., et al. The -1131T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-lll, but not with coronary artery disease: an angiographic study. Atherosclerosis 2007, 191:409-417.
39. De Caterina R., Talmud P.J., Merlini P.A., Foco L., Pastorino R., Altshuler D., et al. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. Atherosclerosis 2011, 214:397-403.
40. Elosua R., Ordovas J.M., Cupples L.A., Lai C.Q., Demissie S., Fox C.S., et al. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res 2006, 47:990-996.
41. Hubacek J.A., Kovar J., Skodova Z., Pit'ha J., Lanska V., Poledne R. Genetic analysis of APOAV polymorphisms (T-1131/C, Serl9/Trp and Vall53/Met): no effect on plasma remnant particles concentrations. Clin Chim Acta 2004, 348:171-175.
42. Laurila P.P., Naukkarinen J., Kristiansson K., Ripatti S., Kauttu T., Silander K., et al. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:346-352.
43. Liu Z.K., Hu M., Baum L., Thomas G.N., Tomlinson B. Associations of polymorphisms in the apolipoprotein A1/C3/A4/A5 gene cluster with familial combined hyperlipidaemia in Hong Kong Chinese. Atherosclerosis 2010, 208:427-432.
44. Evans D., Bode A., von der Lippe G., Beil F.U., Mann W.A. Cerebrovascular atherosclerosis in type III hyperlipidemia is modulated by variation in the apolipoprotein AS gene. Eur J Med Res 2011, 16:79-84.
45. Coca-Prieto I., Valdivielso P., Olivecrona G., Ariza M.J., Rioja J., Font-Ugalde P., et al. Lipoprotein lipase activity and mass, apolipoprotein C-ll mass and polymorphisms of apolipoproteins E and AS in subjects with prior acute hypertriglyceridaemic pancreatitis. BMC Gastroenterol 2009, 9:46.
46. Niculescu L.S., Fruchart-Najib J., Fruchart J.C., Sima A. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome. Clin Chem Lab Med 2007, 45:1133-1139.
47. Niculescu L.S., Vladica M., Sima A.V. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Biochem Biophys Res Commun 2010, 391:587-591.
48. Kisfali P., Mohas M., Maasz A., Hadarits F., Marko L., Horvatovich K., et al. Apolipoprotein AS IVS3+476A allelic variant associates with increased trigliceride levels and confers risk for development of metabolic syndrome in Hungarians. Circ J 2008, 72:40-43.
49. Ong K.L., Jiang C.O., Liu B., Jin Y.L., Tso A.W., Tarn S., et al. Association of a genetic variant in the apolipoprotein AS gene with the metabolic syndrome in Chinese. Clin Endocrinol (Oxf) 2011, 74:206-213.
50. Vasilopoulos Y., Sarafidou T., Bagiatis V., Skriapa L., Goutzelas Y., Pervanidou P., et al. Association between polymorphisms in MTHFR and APOA5 and metabolic syndrome in the Greek population. Genet Test Mol Biomarkers 2011, 15:613-617.
51. Huang X.S., Zhao S.P., Hu M., Bai L., Zhang Q., Zhao W. Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity. Atherosclerosis 2010, 210:563-568.
52. Wu C.K., Chang Y.C., Hua S.C., Wu H.Y., Lee W.J., Chiang F.T., et al. A triglyceride-raising APOA5 genetic variant is negatively associated with obesity and BMI in the Chinese population. Obesity (Silver Spring) 2010, 18:1964-1968.
53. Horvatovich K., Bokor S., Barath A., Maasz A., Kisfali P., Jaromi L., et al. Haplotype analysis of the apolipoprotein AS gene in obese pediatric patients. Int J Pediatr Obes 2011, 6:e318-e325.
54. Chen E.S., Furuya T.K., Mazzotti D.R., Ota V.K., Cendoroglo M.S., Ramos L.R., et al. APOA1/A5 variants and haplotypes as a risk factor for obesity and better lipid profiles in a Brazilian Elderly Cohort. Lipids 2010, 45:511-517.
55. Shcherbakova M., Sinitsin P.A., Gl Poriadina, Larionova V.I., Khmyrova A.P., Petriaikina E.E., et al. Correlation of metabolic syndrome clinical signs and genetic determinants at children with obese. Eksp Klin Gastroenterol 2010, 7:6-11.
56. Smith C.E., Tucker K.L., Lai C.O., Parnell L.D., Lee Y.C., Ordovas J.M. Apolipoprotein A5 and lipoprotein lipase interact to modulate anthropometric measures in Hispanics of Caribbean origin. Obesity (Silver Spring) 2010, 18:327-332.
57. Qi L., Liu S., Rifai N., Hunter D., Hu F.B. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. Atherosclerosis 2007, 192:204-210.
58. Jang Y., Chae J.S., Kim O.Y., Park H.J., Kim J.Y., Paik J.K., et al. APOA5-1131T>C genotype effects on apolipoprotein A5 and triglyceride levels in response to dietary intervention and regular exercise (DIRE) in hypertriglyceridemic subjects. Atherosclerosis 2010, 211:512-519.
59. Suchanek P., Lorenzova A., Poledne R., Hubacek J.A. Changes of plasma lipids during weight reduction in females depends on APOA5 variants. Ann Nutr Metab 2008, 53:104-108.
60. Corella D., Lai C.O., Demissie S., Cupples L.A., Manning A.K., Tucker K.L., et al. APOA5 gene variation modulates the effects of dietary fat intake on body mass index and obesity risk in the Framingham Heart Study. J Mol Med (Berl) 2007, 85:119-128.
61. Sanchez-Moreno C., Ordovas J.M., Smith C.E., Baraza J.C., Lee Y.C., Garaulet M. APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population. J Nutr 2011, 141:380-385.
62. Moreno R., Perez-Jimenez F., Marin C., Moreno J.A., Gomez P., Bellido C., et al. A single nucleotide polymorphism of the apolipoprotein A-V gene -1131T>C modulates postprandial lipoprotein metabolism. Atherosclerosis 2006, 189:163-168.
63. Moreno-Luna R., Perez-Jimenez F., Marin C., Perez-Martinez P., Gomez P., Jimenez-Gomez Y., et al. Two independent apolipoprotein AS haplotypes modulate postprandial lipoprotein metabolism in a healthy Caucasian population. J Clin Endocrinol Metab 2007, 92:2280-2285.
64. Aberle J., Evans D., Beil F.U., Seedorf U. A polymorphism in the apolipoprotein AS gene is associated with weight loss after short-term diet. Clin Genet 2005, 68:152-154.
65. Pruneta-Deloche V., Ponsin G., Groisne L., Fruchart-Najib J., Lagarde M., Moulin P. Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients. Atherosclerosis 2005, 181:403-405.
66. Kovar J., Adamkova V. Lipoprotein lipase activity determined in vivo is lower in carriers of apolipoprotein A-V gene variants 19W and -1131C. Physiol Res 2008, 57:555-561.
67. Feitosa M.F., An P., Ordovas J.M., Ketkar S., Hopkins P.N., Straka R.J., et al. Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status. Atherosclerosis 2011, 215:435-439.
68. Brautbar A., Covarrubias D., Belmont J., Lara-Garduno F., Virani S.S., Jones P.H., et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis 2011, 219:737-742.
69. Cardona F., Guardiola M., Queipo-Ortuno Ml, Murri M., Ribalta J., Tinahones F.J. The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study. Atherosclerosis 2009, 206:148-152.
70. Guardiola M., Ferre R., Salazar J., Alonso-Villaverde C., Coll B., Parra S., et al. Protease inhibitor associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation. Clin Chem 2006, 52:1914-1919.
71. Guardiola M., Ribalta J., Gomez-Coronado D., Lasuncion M.A., de Oya M., Garces C. The apolipoprotein A5 (APOA5) gene predisposes Caucasian children to elevated triglycerides and vitamin E (Four Provinces Study). Atherosclerosis 2010, 212:543-547.
72. Du Ha Yin M., Ye H.Y., Shang Y.J., Dai X.D., Jing W., et al. Expression profiles of lipid metabolism related genes in liver of apoE(-/-)/LDLR(-/-) mice. Zhonghua Bing Li Xue Za Zhi 2007, 36:751-755.
73. Mansouri R.M., Bauge E., Gervois P., Fruchart-Najib J., Fievet C., Staels B., et al. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ Res 2008, 103:450-453.
74. Dorfmeister B., Brandlhofer S., Schaap F.G., Hermann M., Furnsinn C., Hagerty B.P., et al. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats. Diabetologia 2006, 49:1324-1332.
75. Nelbach L., Shu X., Konrad R.J., Ryan R.O., Forte T.M. Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice. J Lipid Res 2008, 49:572-580.
76. Pamir N., McMillen T.S., Li Yl, Lai C.M., Wong H., LeBoeuf R.C. Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis. Metabolism 2009, 58:560-567.
77. Shu X., Nelbach L., Weinstein M.M., Burgess B.L., Beckstead J.A., Young S.G., et al. Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1. Arterioscler Thromb Vasc Biol 2010, 30:2504-2509.
78. Lind U., Nilsson T., McPheat J., Strömstedt P.E., Bamberg K., Balendran C., Kang D. Identification of the human ApoAV gene as a novel RORalpha target gene. Biochem Biophys Res Commun Apr 29 2005, 330(1):233-241.
79. Garelnabi M., Selvarajan K., Litvinov D., Santanam N., Parthasarathy S. Dietary oxidized linoleic acid lowers triglycerides via APOA5/APOClll dependent mechanisms. Atherosclerosis Aug 2008, 199(2):304-309.
80. Mansouri R.M., Baugé E., Gervois P., Fruchart-Najib J., Fiévet C., Staels B., Fruchart J.C. Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ Res Aug 29 2008, 103(5):450-453.
81. Huang X.S., Zhao S.P., Hu M., Bai L., Zhang Q., Zhao W. Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity. Atherosclerosis Jun 2010, 210(2):563-568.
82. Zhang X., Wang J., Chen B. Effect in vitro of apolipoprotein A-V on the structure and functions of recombinant high density lipoprotein. Biochem Biophys Res Commun Oct 22 2010, 401(3):473-479.